Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
Diabetes & Metabolism Journal
; : 338-342, 2018.
Article
en En
| WPRIM
| ID: wpr-716313
Biblioteca responsable:
WPRO
ABSTRACT
The effect of sodium-glucose cotransporter 2 inhibitors on peripheral nerves and kidneys in diabetes mellitus (DM) remains unexplored. Therefore, this study aimed to explore the effect of empagliflozin in diabetic rats. DM in rats was induced by streptozotocin injection, and diabetic rats were treated with empagliflozin 3 or 10 mg/kg. Following 24-week treatment, response thresholds to four different stimuli were tested and found to be lower in diabetic rats than in normal rats. Empagliflozin significantly prevented hypersensitivity (P < 0.05) and the loss of skin intraepidermal nerve fibers, and mesangial matrix expansion in diabetic rats. Results of this study demonstrate the potential therapeutic effects of empagliflozin for the treatment of diabetic peripheral neuropathy and nephropathy.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Nervios Periféricos
/
Piel
/
Estreptozocina
/
Enfermedades del Sistema Nervioso Periférico
/
Usos Terapéuticos
/
Diabetes Mellitus
/
Diabetes Mellitus Experimental
/
Nefropatías Diabéticas
/
Neuropatías Diabéticas
/
Transportador 2 de Sodio-Glucosa
Límite:
Animals
Idioma:
En
Revista:
Diabetes & Metabolism Journal
Año:
2018
Tipo del documento:
Article